Item 8.01 Other Events.

On September 7, 2021, NeuroOne Medical Technologies Corporation (the "Company") issued a press release announcing that the Company received U.S. Food and Drug Administration 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





 (d) Exhibits




Exhibit No.   Description

99.1            Press Release, dated September 7, 2021
104           Cover Page Interactive Data File (embedded within Inline XBRL document).




                                       1

© Edgar Online, source Glimpses